The purpose of MedCap’s investor relations
- To provide capital markets with up-to-date, relevant and balanced information to ensure good liquidity and a fair share price.
- To ensure compliance with applicable rules and regulations.
- To ensure that investors perceive MedCap as accessible, reliable and professional.
All communications from MedCap should be published in a timely manner, and be accurate and up to date. Published information must be in compliance with the EU’s Market Abuse Regulation, applicable laws and regulations, and Nasdaq’s rules for issuers, including guidelines and recommendations from Nasdaq Stockholm.
Reviewing analyst reports
If and when MedCap is requested by analysts to review draft reports, such review must be limited to corrections of facts and information that are publicly known, and to general discussion of the driving forces in the industry and factors affecting market growth. Financial models must not be reviewed.
To reduce the risk of information leakage, and to avoid suspicion that stakeholders may have gained access to insider information, MedCap applies a quiet period during the 30 days prior to publication of year-end and interim reports. During this period, representatives of MedCap must refrain from answering questions or commenting on financial performance, and should refer to the quiet period. However, obvious factual errors may be pointed out or confirmed when an analyst requests comments on research and reports, provided that the information on the matter of fact is publicly available. It may also be permissible to provide information about circumstances that have previously been made public, and to correct misunderstandings, erroneous calculations and verifiable errors, and to provide industry statistics – all provided the underlying facts are publicly available. No comments regarding forward-looking financial information are permissible.
Publication of financial results
Releases of financial reports should be submitted to the relevant news services and be made available prior to meetings with analysts and conference calls, in accordance with the decisions of the IR function. MedCap’s other primary communication channels with investors are conference calls and webcasts, and meetings with investors, including roadshows, industry and investor conferences, capital market days and other informational events.